Efficacy of early treatment with infliximab in pediatric Crohn&rsquo;s disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 14

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Apr 14, 2010; 16(14): 1776-1781
Published online Apr 14, 2010. doi: 10.3748/wjg.v16.i14.1776

Table 1 Baseline characteristics

Gender (male/female)	27/9
Median age (range, yr)	13 (1-16)
Duration of follow up [mean (range), mo]	51.9 (24-101)
Disease location
Small intestine	3
Colon	10
Small intestine & colon	23
PCDAI at diagnosis (mean ± SD)	32.9 ± 8.6

PCDAI: Pediatric Crohn’s disease activity index.

Citation: Lee JS, Lee JH, Lee JH, Lee HJ, Kim MJ, Lee HJ, Choe YH. Efficacy of early treatment with infliximab in pediatric Crohn’s disease. World J Gastroenterol 2010; 16(14): 1776-1781
URL: https://www.wjgnet.com/1007-9327/full/v16/i14/1776.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i14.1776

Lee JS, Lee JH, Lee JH, Lee HJ, Kim MJ, Lee HJ, Choe YH. Efficacy of early treatment with infliximab in pediatric Crohn’s disease. World J Gastroenterol 2010; 16(14): 1776-1781 [PMID: 20380012 DOI: 10.3748/wjg.v16.i14.1776]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.